Antimicrobial development in the era of emerging resistance
Metadatos
Mostrar el registro completo del ítemAutor
Sorlozano Puerto, Antonio; Carrasco, Cristina; Cabeza, José; Villegas Martínez, Enrique; Gutiérrez Fernández, JoséEditorial
Bentham Science Publishers
Materia
Faropenem Dalbavancin Telavancin Oritavancin Ceftobiprole Iclaprim
Fecha
2009-07Referencia bibliográfica
Sorlozano A, Carrasco C, Cabeza J, Villegas E, Gutierrez J. Antimicrobial development in the era of emerging resistance. Mini Rev Med Chem. 2009 Jul;9(8):938-55. DOI:10.2174/138955709788681564
Resumen
Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.